BMI evolution and impaired oGTT in a sample of psychotic resistant patients that starting clozapine

Marina Garriga; Andrea Mallorquí; M. Brat; Eva Solé; Iría Grande; Sílvia Amoretti; Eduard Vieta; Clemente García‐Rizo; Miquel Bernardo

doi:10.1016/j.euroneuro.2018.11.796

Related publications

Article2017

Food craving evolution in schizophrenic patients starting treatment with clozapine

Marina Garriga, Andrea Mallorquí, Lourdes Serrano, Manel Salamero, Eduard Vieta, Miquel Bernardo, Clemente García‐Rizo

Article2019

Food craving and consumption evolution in patients starting treatment with clozapine

Marina Garriga, Andrea Mallorquí, Lourdes Serrano, José Ríos, Manel Salamero, Eduard Parellada, Marta Gómez-Ramiro, Cristina Oliveira, Sílvia Amoretti, Eduard Vieta, Miquel Bernardo, Clemente García‐Rizo

Article2021

Clozapine in patients with schizoaffective disorder: A systematic review

Diana Rey Souto, Justo Pinzón-Espinosa, Eduard Vieta, Antoni Benabarre Hernández

Article2023

Nurse-led lifestyle intervention in a cohort of schizophrenia patients treated with clozapine

Andrea Mallorquí, Cristina Oliveira, José Ríos, Maria Pilar Isla-Pera, Joaquín Gil-Badenes, Sílvia Amoretti, Miquel Bernardo, Eduard Vieta, Eduard Parellada, Marina Garriga, Clemente García‐Rizo

Article2017

Neurocognition in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia

Estela Jiménez‐López, Ana Isabel Aparicio, Eva María Sánchez‐Morla, Roberto Rodríguez–Jiménez, Eduard Vieta, José Luis Santos